AOD-9604

Thorner, M. O., et al. (1993). "Growth hormone-releasing peptide-6: A novel synthetic hexapeptide with potent growth hormone-releasing activity." Neuroendocrinology, 57(5), 785-794.

GHRP-6 is commonly discussed in research protocols for administration on an empty stomach to maximize its effect on GH release and minimize potential attenuation by elevated glucose or fatty acid levels. Multiple daily administrations are often used to maintain elevated GH pulsatility.

• GHRH Analogs (e.g., CJC-1295, Sermorelin)

  Combination use is commonly discussed in research for significantly enhanced GH pulsatility due to their distinct mechanisms of action on GH release. Often co-administered.

  Synergistic

• Insulin

  Insulin may blunt GH release. Research protocols often administer GHRP-6 on an empty stomach, away from insulin or carbohydrate intake, to maximize GH response. Caution is advised for those managing blood sugar.

  Monitor Combination

• Somatostatin Analogues

  Somatostatin inhibits GH release. Co-administration would counteract the primary effect of GHRP-6. Therefore, these are typically avoided in research protocols.

  Avoid

• Corticosteroids

  Corticosteroids can reduce the body's natural GH secretion. While not a direct interaction, they may reduce the efficacy of GHRP-6, requiring researchers to note potential attenuation of effects.

  Use Caution

• Foods/Nutrients (especially carbohydrates/fats)

  Ingestion of food, particularly carbohydrates and fats, can attenuate GH release stimulated by GHRP-6. Research protocols often specify administration on an empty stomach (30-60 minutes before meals or 2-3 hours after).

  Monitor Combination

• Other GH Secretagogues (e.g., Ipamorelin, GHRP-2)

  While theoretically they could be combined, research protocols typically focus on one GHRP at a time to isolate effects. Combining multiple GHRPs may not yield significantly greater benefits and could increase side effects.

  Use Caution

1. 1Gather supplies: GHRP-6 vial, bacteriostatic water (BAC water), sterile insulin syringe, alcohol wipes.
2. 2Clean the rubber stopper of the GHRP-6 vial and the BAC water vial with alcohol wipes.
3. 3Draw the desired amount of BAC water into the syringe (e.g., 1ml for 5mg vial, resulting in 5mg/ml concentration).
4. 4Slowly inject the BAC water into the GHRP-6 vial, directing it down the side of the vial to avoid direct impact on the powder.
5. 5Do not shake the vial. Gently swirl the vial between your palms for several minutes to allow the powder to dissolve completely. If necessary, place in a refrigerator for a short period and swirl again.
6. 6Once fully dissolved, the solution should be clear and free of particles. Store as directed.

Handle the lyophilized powder gently. Avoid shaking the vial vigorously during reconstitution to prevent denaturation of the peptide.

• Weeks 1-2: Researchers often report initial increases in appetite and potentially improved sleep quality. Some may observe subtle improvements in energy levels.
• Weeks 3-6: More noticeable improvements in body composition, such as increased lean muscle mass and decreased fat mass, may become apparent in research subjects. Enhanced recovery from exercise is also commonly discussed.
• Weeks 7-12: Significant changes in body composition are typically observed, with sustained improvements in muscle strength, endurance, and overall physical performance. Researchers may document continued fat loss.
• Post-cycle: Benefits may gradually diminish if administration is discontinued, highlighting the need for sustained research protocols to maintain effects.
• Individual responses vary widely among research subjects due to genetic factors, diet, and training regimens.